GlassScriptPhysician profile
Joyce Chin
NPI 1235541319
$2,867.03
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,090 · 2020: $235 · 2021: $421 · 2022: $122.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $387.28 | 2019 | |
| Exelixis INC. | $354.96 | 2019 | |
| Dynavax Technologies Corporation | $242.15 | 2019 | |
| Adamas Pharmaceuticals, INC. | $237.27 | 2019-2020 | |
| Amgen INC. | $232.44 | 2020-2021 | |
| Biogen, INC. | $182.75 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $144.90 | 2019 | |
| Shire North American Group INC | $142.54 | 2019 | |
| Celgene Corporation | $125.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2021 | |
| Astellas Pharma US INC | $124.71 | 2019 | |
| Acadia Pharmaceuticals INC | $121.61 | 2022 | |
| Alexion Pharmaceuticals, INC. | $120.24 | 2019 | |
| Puma Biotechnology, INC. | $115.46 | 2019 | |
| Glaxosmithkline, LLC. | $109.23 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $101.49 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Chin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.